252-OR: Virtual Multidisciplinary Lifestyle Intervention Is as Effective as the Physical Program for Patients with Diabetes and Obesity during COVID-19 Pandemic

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 252-OR
Author(s):  
MARWA AL-BADRI ◽  
CARA L. KILROY ◽  
JACQUELINE I. SHAHAR ◽  
SHAHEEN TOMAH ◽  
HANNAH GARDNER ◽  
...  
Keyword(s):  
Lifestyle Intervention ◽  
Patients With Diabetes ◽  
Physical Program ◽  
Diabetes And Obesity

Changes induced by metabolic surgery on the main components of glucose/insulin system in patients with diabetes and obesity

2020 ◽  
Author(s):  
Elisabetta Rinaldi ◽  
Maria Grazia Zenti ◽  
Maddalena Trombetta ◽  
Giulia Ceradini ◽  
Anna Altomari ◽  
...  
Keyword(s):  
Metabolic Surgery ◽  
Patients With Diabetes ◽  
Main Components ◽  
Diabetes And Obesity

scholarly journals Empowerment in the Treatment of Diabetes and Obesity

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Włodzimierz Łuczyński ◽  
Barbara Głowińska-Olszewska ◽  
Artur Bossowski
Keyword(s):  
Standard Of Care ◽  
Patients With Diabetes ◽  
Treatment Of Diabetes ◽  
Based Medicine ◽  
Diabetes And Obesity ◽  
Positive Effect

As the available therapies for diabetes and obesity are not effective enough, diabetologists and educators search for new methods to collaborate with patients in order to support their health behaviors. The aim of this review is to discuss perspectives for the development of new empowerment-type therapies in the treatment of diabetes/obesity. Empowerment is a process whereby patients gain the necessary knowledge to influence their own behavior to improve the quality of their lives. It is carried out in five stages: (1) identify the problem, (2) explain the feelings and meanings, (3) build a plan, (4) act, and (5) experience and assess the execution. Although many years have passed since the advent and popularization of the concept of empowerment, the area remains controversial, mainly with regard to the methodology of therapy. Some previous studies have confirmed the positive effect of empowerment on body weight, metabolic control, and quality of life of patients with type 2 diabetes; however, few studies have been conducted in patients with type 1 diabetes. There is still a need to confirm the effectiveness of empowerment in accordance with Evidence Based Medicine by performing long-term observational studies in a large group of patients. In future, empowerment may become part of the standard of care for patients with diabetes and/or obesity.

Metabolic Surgery Counseling, Diabetes Remission, and A1C Control in Patients with Diabetes and Obesity

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2101-P
Author(s):  
LEE-SHING CHANG ◽  
SHERVIN MALMASI ◽  
NAOSHI HOSOMURA ◽  
HUABING ZHANG ◽  
CHRISTOPHER J. BROWN ◽  
...  
Keyword(s):  
Metabolic Surgery ◽  
Diabetes Remission ◽  
Patients With Diabetes ◽  
Diabetes And Obesity

scholarly journals Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)

2020 ◽  
Author(s):  
Shiv Kumar Sarin ◽  
Ashok Choudhury ◽  
George K Lau ◽  
Ming-Hua Zheng ◽  
Dong Ji ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Injury ◽  
Clinical Status ◽  
Chronic Liver ◽  
Asian Countries ◽  
Injury Patterns ◽  
Multisystem Involvement ◽  
Patients With Diabetes ◽  
Acute Decompensation ◽  
Diabetes And Obesity

Abstract Background and Aims: COVID-19 is a dominant pulmonary disease, with multisystem involvement, depending upon co morbidities. Its profile in patients with pre-existing chronic liver disease (CLD) is largely unknown. We studied the liver injury patterns of SARS-Cov-2 in CLD patients, with or without cirrhosis. Methods: Data was collected from 13 Asian countries on patients with CLD, known or newly diagnosed, with confirmed COVID-19. Result: Altogether, 228 patients [185 CLD without cirrhosis and 43 with cirrhosis] were enrolled, with comorbidities in nearly 80%. Metabolism associated fatty liver disease (113, 61%) and viral etiology (26, 60%) were common. In CLD without cirrhosis, diabetes [57.7% vs 39.7%, OR=2.1(1.1-3.7), p=0.01] and in cirrhotics, obesity, [64.3% vs. 17.2%, OR=8.1(1.9-38.8), p=0.002) predisposed more to liver injury than those without these. Forty three percent of CLD without cirrhosis presented as acute liver injury and 20% cirrhotics presented with either acute-on-chronic liver failure [5(11.6%)] or acute decompensation [4(9%)]. Liver related complications increased (p<0.05) with stage of liver disease; a Child-Turcotte Pugh score of 9 or more at presentation predicted high mortality [AUROC-0.94, HR=19.2(95CI 2.3-163.3), p<0.001, sensitivity 85.7% and specificity 94.4%). In decompensated cirrhotics, the liver injury was progressive in 57% patients, with 43% mortality. Rising bilirubin and AST/ALT ratio predicted mortality among cirrhosis. Conclusions: SARS-Cov-2 infection causes significant liver injury in CLD patients, decompensating one fifth of cirrhosis, and worsening the clinical status of the already decompensated. The CLD patients with diabetes and obesity are more vulnerable and should be closely monitored.

Sign in / Sign up

Export Citation Format

Share Document